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Stephen T HolgateAbstract
IgE has long been known as a therapeutic target for allergic disease, but the difficulty has been in selecting agents
that don't trigger cross linkage of IgE when bound to its high affinity receptor (FceR1) on mast cells and basophils.
By “designing” a monoclonal antibody (mAb) which targets that part of IgE that binds to that binds to the a-chain
of FceR1, the allergic cascade can be effectively interrupted and diseases such as asthma greatly improved, providing
a substantial part of their phenotype engages IgE. Clinical trials and real life studies confirm this. Beyond asthma, a
whole range of other diseases dependent upon IgE initiation and triggering are being identified. These diseases are
now being explored as being amenable to anti-IgE therapy some of which are comorbidities of asthma and others
not. The advent of an even more potent anti-IgE mAb - QGE031 – is creating further opportunities for anti-IgE therapy
to improve the lives of so many people with IgE-related diseases.
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IgE as a therapeutic target in allergic disease
Carl Prausnitz and Heinz Küstner first described the
passive transfer of the allergen-specific response in the
skin with serum in 1921 [1]. They called the “substance”
present in the serum reagin. It took a further 45 years
before Kimishige Ishizaka, Gunnar Johansson and Hans
Bennich identified reagin as the 5th immunoglobulin
class, immunoglobulin (Ig)E [2]. Subsequently, the me-
chanism of cell activation through which cross-linkage
of cell bound IgE on mast cells and basophils was shown
to involve dimerisation of the high affinity IgE receptor,
FcεR1, leading to non-cytotoxic degranulation and gener-
ation of newly formed lipid mediators responsible for the
acute allergic response. The later recognition that both
mast cells and basophils can also release preformed and
newly generated cytokines, chemokines and growth factors
helps explain how the acute allergic response transits into
late-phase and more chronic responses associated with
leukocyte recruitment and activation of tissue remodelling
pathways [3]. More recently FcεR1 has also been found on
antigen-presenting dendritic cells (DCs) where they func-
tion to facilitate the uptake and processing of allergens to
enhance sensitisation [4]. Thus, identification of IgE as aCorrespondence: sth@soton.ac.uk
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been known for many years, but the difficulty has been in
identifying therapeutic agents that could block its effects.Anti-IgE mAbs; the first biologics for treating allergic
diseases
A major breakthrough occurred when it was shown that
the Cε3 region of the Fc fragment of IgE binds very
selectively to a particular component of the α-chain of
the tetrameric FcεR1 (α1β1γ2) [5]. This enabled blocking
immunoglobulin to be raised against IgE and specifically
to the Cε3 region and as a consequence avoid cross-
linking of IgE bound to its high affinity receptor. Starting
in mice [6], a chimeric IgG mAb active in humans was
produced and shown to be effective in reducing circulating
IgE without causing an anaphylactic response [7]. By
humanising IgG1 anti-human IgE mAb containing only the
antigen binding site as mouse sequences, omalizumab was
born [8]. After successful Phase 2 proof of concept studies
on allergen induced EAR and LAR and allergen-triggered
skin wheal and flare reaction, omalizumab successfully
entered the clinic for the treatment of severe allergic
asthma in both adults and children over the age of 12 years
reviewed in [9].Omalizumab clinical profile
With a good safety record, many clinical studies con-
firmed efficacy in severe asthma which have now extendedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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zumab and increased malignancy have recently been largely
dispelled by the large postmarketing EXCELS (Evaluating
Clinical Effectiveness and Long-term Safety in Patients
with Moderate-to-Severe Asthma) study indicating that
omalizumab therapy is not associated with an increased
risk of malignancy [11]. As with other humanised anti-
bodies, there remains, however occasional anaphylactic-
type responses which sometimes can be delayed for which
a mechanism has yet to be found [12].
Two issues are important to recognise in the clinical
use of omalizumab; the dosing according to the circulating
levels of serum total IgE (700 iu/ml being the upper limit
for inclusion) and body weight and the responder/non-
responder patients that so far cannot be differentiated on
the basis of known biomarkers. The latter problem man-
dates an assessment of efficacy after 16 weeks of treatment
using both practitioner and patient assessment of outcome
measures [13]. Another important feature of omalizumab’s
clinical efficacy is the formation of IgG/IgE trimeric and
hexameric immune complexes without complement acti-
vation or any other toxicity. High levels of circulating IgE
results in an increase in FcεR1 on effector cells whereas
removal of IgE with omalizumab causes down-regulation
of FcεR1 on these cells and undoubtedly contributes
to the efficacy of this treatment [14]. Blockade of IgE
reduces the allergic inflammatory cascade including
eosinophil and basophil recruitment probably by com-
bined effects influencing allergen sensing and processing
by airway DCs (Figure 1) [15] and blockade of medi-
ator secreting cells. However, counter intuitively, inhib-
ition of these cellular and mediator events with
omalizumab does not appear to reduce non-specific air-
ways responsiveness (such as methacholine and hista-
mine PC20) at least in the intermediate term [16], but
do inhibit measures of indirect responsiveness such
as adenosine and exercise which involve mast cell acti-
vation [17]. This might suggest that internalisation of
FcεR1induced when IgE is removed results in “quietening”
of mast cell releasability to stimuli other than mediated
directly through IgE e.g. the adenosine A2b-receptor
mast cell activation pathway.
A fascinating aspect of the therapeutic response of
omalizumab in severe allergic asthma is the powerful
effect it has on asthma exacerbations, patient-related and
quality of life measures, but less effect on measures of
lung function. Part of the reason for this relatively poor
response on lung function could be the result of prior
maximum bronchodilator and anti-inflammatory effects of
corticosteroids and long-acting β2-agonists (LABAs) which
all patients being selected for treatment with omalizumab
will be receiving. However, what is most gratifying is the
ability in both adults and children for oral and high dose
inhaled corticosteroids to be reduced and, in some cases,stopped altogether with a reduction in corticosteroid co-
morbidities without loss of asthma control [18,19]. Also
of importance is the marked effect of omalizumab in
reducing emergency physician consultations, courses of
oral corticosteroids and hospital admissions associated
with severe exacerbations.
Although severe asthma in children is less frequent
than in adults, when it does occur it is most frequently
associated with atopy and atopic comorbidities such as
atopic dermatitis, allergic rhinitis and food allergy. Omali-
zumab is equally effective in children [20]. Omalizumab,
therapy also reduces the September epidemic of childhood
asthma in inner city US severe asthma thereby strengthen-
ing link between allergic and viral mechanisms in such
children [21].Does omalizumab influence airway remodelling in chronic
asthma?
A key question is what the long-term effect of omalizu-
mab is on airway wall remodelling in chronic asthma.
This has been approached by assessing airway wall thick-
ness by computed tomography (CT). One study by
Hoshino and colleagues [22] conducted on 30 patients
with severe persistent asthma showed that omalizu-
mab for 16 weeks significantly reduced airway wall
area that correlated with reduced sputum eosinophila
and increase in baseline lung function. A further stu-
dy has shown that 50% of omalizumab responders
exhibit a reduction in epithelial reticular basement mem-
brane (RBM) thickening suggesting effects on remo-
delling [23].Systemic actions of omalizumab on asthma comorbidities
and allied “allergic” conditions
In administering an anti-allergy therapy systemically, there
are likely to be powerful effects on other allergic manifes-
tations in addition to asthma (Figure 2) [24]. Some rando-
mised and observational trials, as well as case studies, have
shown that omalizumab is efficacious in patients with
allergic rhinitis, bronchopulmonary allergic aspergillosis,
eosinophilic otitis media, urticaria, Kimura’s disease (sub-
cutaneous granuloma of soft tissues in the head and neck
region, increased eosinophil counts and high serum IgE
levels), food allergy and idiopathic and exercise-induced
anaphylaxis, atopic dermatitis, protection from anaphylaxis
during allergen immunotherapy, latex allergy, cutaneous
mastocytosis, eosinophilic gastroenteritis, nasal polyposis
and even some cases of intrinsic asthma (Figure 2, Table 1).
Of these, the dramatic effect of anti-IgE treatment of
chronic urticarial and angioedema is especially valuable
since the therapeutic options for such patients are very
limited beyond anti-histamines, oral corticosteroids and
immunosuppressants [25]. While urticarial can occur
Figure 1 Reduce levels of circulating free IgE by interacting with omalizumab to form immune complexes prevents IgE interaction
with cell surface high-affinity IgE receptors (FcóεRI) expressed on dendritic cells, mast cells and basophils and also results in inhibition
of FcεRI expression to enhance inhibitory effects on the allergic cascade.
Figure 2 Diseases in which anti-IgE therapy with omalizumab has been claimed to be efficacious. Intrinsic (or non-allergic asthma) has
revealed efficacy in some anecdotal reports.
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Table 1 Diseases in which ant-IgE has been reported to exhibit efficacy
Disease Responsiveness to omalizumab Reference
Non-allergic asthma Some reported benefits, but
controversial
- Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A,
Zucchi L. Long-term benefits of omalizumab in a patient with
severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011; 7: 9.
- Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM.
Effectiveness of omalizumab in non-allergic severe asthma. J Biol
Regul Homeost Agents. 2013; 27: 45–53.
Churg-Strauss (C-S) Syndrome Anecdotal evidence of efficacy, but
also reports of uncovering latent
C-S disease
- Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J.Administration
of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy
Immunol. 2007; 144: 155–8.
- Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-strauss
syndrome in patients treated with omalizumab. Chest. 2009;
136: 507–18.
Allergic rhinitis Well documented benefit, but
questionable cost-effectiveness
- Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis.
Expert Opin Biol Ther. 2013; 13: 933–45.
Atopic dermatitis (AD, eczema) Efficacious in severe refractory AD - Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Anti-immunoglobulin E
in the treatment of refractory atopic dermatitis. Clin Exp Dermatol.
2013; 38: 496–500.
- Sánchez-Ramón S, Eguíluz-Gracia I, Rodríguez-Mazariego ME,
Paravisini A, Zubeldia-Ortuño JM, Gil-Herrera J, Fernández-Cruz E,
Suárez-Fernández R. Sequential combined therapy with omalizumab
and rituximab: a new approach to severe atopic dermatitis. J Investig
Allergol Clin Immunol. 2013; 23: 190–6.
Nasal polyposis Efficacious in allergic and non-allergic
polyposis
- Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W,
Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C.
Omalizumab is effective in allergic and nonallergic patients with nasal
polyps and asthma. J Allergy Clin Immunol. 2013; 131: 110–6.
Bronchopulmonary
allergic aspergillosis
Limited evidence. Requires further
study
- Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic
bronchopulmonary aspergillosis in people with cystic fibrosis.
Cochrane Database Syst Rev. 2013; 9: CD010288.
Food allergy In conjunction with allergen
immunotherapy
- Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT.
A pilot study of omalizumab to facilitate rapid oral desensitization in
high-risk peanut-allergic patients. Allergy Clin Immunol. 2013;
132: 1368–74.
- Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral
desensitization in combination with omalizumab therapy in patients
with cow's milk allergy. J Allergy Clin Immunol. 2011; 127: 1622–4.
Chronic (idiopathic) urticaria
and angioedema
Active independent of known
engagement of IgE-driven pathways
- Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A,
Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the
treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med.
2013; 368: 924–35.
- Lang DM. A critical appraisal of omalizumab as a therapeutic option
for chronic refractory urticaria/angioedema. Ann Allergy Asthma
Immunol. 2014; 112: 276–9.
Kimura’s disease Anecdotal evidence - Nonaka M, Sakitani E, Yoshihara T. Anti-IgE therapy to Kimura's disease:
A pilot study. Auris Nasus Larynx. 2014; 41: 384–8.
Eosinophilic otitis media Limited evidence for efficacy - Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H,
Yoshida N. Clinical efficacy of anti-IgE therapy for eosinophilic otitis
media. Otol Neurotol. 2012; 33: 1218–24.
- Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H,
Yoshida N. Effect of omalizumab on biomarkers in middle ear effusion
in patients with eosinophilic otitis media. Acta Otolaryngol. 2014;
134: 366–72.
Mastocytosis Anecdotal case reports - Kibsgaard L, Skjold T, Deleuran M, Vestergaard C. Omalizumab Induced
Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent
Systemic Mastocytosis. Acta Derm Venereol. 2014; 94: 363–364.
- Matito A, Blázquez-Goñi C, Morgado JM, Alvarez-Twose I, Mollejo M,
Sánchez-Muñoz L, Escribano L.Short-term omalizumab treatment in an
adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol.
2013; 111: 425–6.
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Table 1 Diseases in which ant-IgE has been reported to exhibit efficacy (Continued)
Eosinophilic gastroenteritis
and oesophagitis
Probably ineffective - Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, Dias JA.
Omalizumab in the treatment of eosinophilic esophagitis and food
allergy. Eur J Pediatr. 2011; 170: 1471–4.
- Stone KD, Prussin C. Immunomodulatory therapy of eosinophil-
associated gastrointestinal diseases. Clin Exp Allergy. 2008; 38: 1858–65.
Latex allergy Limited evidence for efficacy - Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I,
Guyomarch-Cocco L, Trunet P. Effect of omalizumab in health care




Anecdotal. - Bray SM, Fajt ML, Petrov AA. Successful treatment of exercise-induced
anaphylaxis with omalizumab. Ann Allergy Asthma Immunol. 2012;
109: 281–2.
Also in conjunction with
allergen-specific immunotherapy
- Demirtürk M, Gelincik A, Colakoğlu B, Dal M, Büyüköztürk S.
Promising option in the prevention of idiopathic anaphylaxis:
omalizumab. J Dermatol. 2012; 39(6): 552–4.
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especially food allergy, it most frequently occurs as an
“idiopathic form” where no known external allergies are
found; nevertheless anti-IgE therapy can still be highly
effective in such patients event in the absence of auto-
antibodies against IgE or FcεR1 (see Chapter by Sarbjit
Saini in this series of reviews). While all of these indica-
tions must indicate some role for IgE in pathophysiology,
this may not always be obvious (as in urticaria). One
possibility is that the quieting of mast cell releasability
with loss of the cell surface FcεR1 during omalizumab
treatment raises the threshold for mast cell activation
independent of the stimulus. Such beneficial effects across
a range of allergic disorders is likely to be an important
factor in the improvement in quality of life and wellbeing
encountered in the severe allergic asthma trials and man-
dates the derivation of a new set of outcome measures that
capture these in complex multisystem allergy as has proven
so useful in other complex immunological diseases such as
rheumatoid arthritis and SLE.
A new more potent anti-IgE mAb in development
An exciting new development is the production of a
much more potent form of anti-IgE, QGE031 (Novartis),
which is at least 12 times more potent than omalizumab
for the treatment of IgE-driven diseases where a significant
unmet need exists such as severe uncontrolled asthma,
atopic dermatitis and food allergies [26]. Bullous pemphig-
oid is also a potential disease with high morbidity in which
QGE031 could be active on account of its increased
activity on IgE-mediated skin responses and its prolonged
duration of action [27].
In conclusion:
– Clinical trials have repeatedly shown that anti-IgE
is highly effective in reducing exacerbations and
reducing corticosteroid use, as well as baseline
control of asthma in adults and children.– Reduced use of health services such as hospital
admission, ICU etc. makes the economic case for
omalizumab in managing high risk severe asthma.
– Omalizumab is active on asthma comorbidities as
well as other conditions, presumably related to
allergy and/or IgE.
– There appear to be some long term benefits
of omalizumb on airway wall remodelling.
– A more active anti-IgE mAb is in development.
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